| Name | β-Aminoarteether |
| Description | β-Aminoarteether (SM934 free base), an orally active derivative of Artemisinin, serves a pivotal role in the research of inflammation and autoimmune disorders, including those related to lupus diseases. |
| In vitro | β-Aminoarteether (SM934; 10 μM; 24 hours) directly increases IL-10 production and reduces IL-12/23p40 production in primary peritoneal macrophages upon IFN-γ stimulation [1]. Additionally, in vitro, β-Aminoarteether (SM934) inhibits Th1 and Th17 polarization without affecting Treg differentiation [1]. |
| In vivo | Treatment with β-Aminoarteether (SM934; orally administered at doses of 1-10 mg/kg daily for 3 months) substantially slowed the advancement of glomerulonephritis and enhanced survival rates in female NZB/W F1 mice aged six and a half months [1]. Additionally, β-Aminoarteether therapy bolstered the production of IL-10 by macrophages derived from these mice [1]. This indicates a promising therapeutic potential for managing glomerulonephritis in this mouse model. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.11 mM), Sonication is recommended.
DMSO : 60 mg/mL (183.25 mM), Sonication is recommended.
|
| Keywords | SM-934 | SM934 | SM 934 | beta-Aminoarteether | b-Aminoarteether |
| Inhibitors Related | Stavudine | Ascorbyl palmitate | Citraconic acid | Trimethylamine N-oxide | Teneligliptin hydrobromide | NLRP3-IN-2 | Aluminum Hydroxide | N4-Acetylcytidine | (S)-(+)-Carvone | MCC950 | Articaine hydrochloride | Isoandrographolide |
| Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
United States
